Folio · SPXSet Report · Digest
v0.7.0 STABLE · 2026-11-11 · r4

2026-W46 · Nov 9–Nov 15 · Company · Profile · published

Index >>> Company >>> Profile

DexCom, Inc. (DXCM) — XLV Health Care · S&P 500 Profile |德康公司介紹

health-careS&P500xlv
SPXSet Studio
IN-HOUSE RESEARCH · 站內獨立研究

DexCom, Inc. (DXCM) — Business, History & S&P 500 Profile |德康公司介紹

DexCom company profile · continuous glucose monitoring (CGM) systems · history · financial snapshot · S&P 500 rank #314 · 德康公司業務歷史財務與標普500地位

中文版 ↓

PROFILE
Market data as of Nov 3, 2026 (benchmark snapshot)
Financials: FY2025 (ended Dec 31, 2025)
MARKET CAP
$31.61B
Nov 3, 2026 (StockAnalysis)
S&P 500 WEIGHT
0.05%
Rank #314 · Nov 3, 2026 (Slickcharts)
FY2025 REVENUE
$4.66B
+16% YoY
FY2025 NET INCOME
$836.3M
Diluted EPS $2.09 · +47.2% YoY

SNAPSHOT

TickerDXCM (Nasdaq)
CompanyDexCom, Inc.
GICS sector / industryHealth Care / Health Care Equipment
S&P 500 rank (by weight)#314 · 0.05% (Nov 3, 2026)
Sector rank (by S&P 500 weight)#42 in Health Care (Nov 3, 2026)
HeadquartersSan Diego, California
Founded1999
CEOJacob S. Leach
Employees≈11,100 (Dec 31, 2025, FY2025 10-K)
Market cap$31.61B (Nov 3, 2026)
SEC filingsEDGAR — CIK 0001093557

WHAT IT DOES

DexCom designs, manufactures and sells continuous glucose monitoring (CGM) systems for diabetes and metabolic-health management. Its G7 system, cleared in the United States for people with diabetes aged two and older, and the G7 15 Day system, cleared in April 2025 for adults, give real-time glucose readings without routine fingersticks and connect to phones, watches and insulin-delivery partners.

FY2025 revenue was $4,662.0M, up 16% from $4,033.0M in FY2024, and net income was $836.3M, up 45% from $576.2M. Gross profit was $2,801.9M, a 60.1% gross margin (computed: gross profit divided by revenue). The United States supplied 71.5% of revenue and international markets 28.5%. DexCom sells through distributors (84.9% of revenue, computed) and directly (15.1%, computed).

Beyond diabetes, DexCom launched Stelo in August 2024 as the first over-the-counter glucose biosensor in the United States, aimed at adults with prediabetes and Type 2 diabetes who do not use insulin. Manufacturing sits in Mesa, Arizona; Batu Kawan, Malaysia; and Athenry, Ireland, with headquarters and research in San Diego.

REVENUE BY GEOGRAPHY — FY2025

SegmentRevenueShareYoY
United States$3,334.9M71.5%+15%
International$1,327.1M28.5%+16%
Total revenue$4,662.0M100%+16%
Source: DexCom FY2025 Form 10-K, revenue disaggregation note. DexCom reports one business activity, CGM systems, disaggregated by geography and by sales channel; channel split for FY2025: distributor $3,959.0M, direct $703.0M (shares computed). Shares and YoY are computed from the 10-K comparatives; rows sum to the total (rounding).

HISTORY

YearMilestone
1999Founded in San Diego, California, to develop continuous glucose monitoring technology
2006Receives FDA approval and commercializes its first CGM product
2018G6 receives FDA marketing authorization, the first CGM permitted as part of an integrated system with compatible devices
2023G7 launches, with FDA authorization in December 2022 and CE Mark in March 2022
2024Stelo launches in August as the first over-the-counter glucose biosensor in the United States
2025G7 15 Day receives FDA marketing authorization in April; DexCom says it will transition G6 customers to G7 and G7 15 Day by the end of 2026

COMPETITIVE POSITION

  • Category leadership in CGM — DexCom, Abbott and Medtronic dominate prescription CGM; DexCom competes on accuracy (G7 15 Day MARD 8.0% per the 10-K), wear time, connectivity and payer coverage rather than on price alone.
  • Platform breadth — the same sensor platform serves intensive insulin users (G7), longer-wear adults (G7 15 Day) and non-insulin users (Stelo), widening the addressable market beyond Type 1 diabetes.
  • Distribution reach — distributors carry 84.9% of revenue, so pharmacy and distributor relationships, not just direct sales, decide access and growth.
  • Competition — Abbott Libre, Medtronic Guardian and emerging biosensor entrants contest accuracy, price and insulin-pump integration; loss of a major distributor or payer contract would be material, per the 10-K concentration disclosure.

FINANCIAL SNAPSHOT — FY2025

Revenue$4,662.0M (+16% YoY)
Cost of sales$1,860.1M
Gross profit$2,801.9M (60.1% margin, computed)
Research and development$599.1M
Selling, general and administrative$1,291.0M
Operating income$911.8M (vs $600.0M in FY2024)
Net income$836.3M (+45% YoY)
Diluted EPS$2.09 (vs $1.42 in FY2024)
Total assets$6,339.9M (Dec 31, 2025)
Stockholders’ equity$2,746.0M (Dec 31, 2025)
Source: DexCom FY2025 Form 10-K consolidated statements. Gross margin is computed from the 10-K figures. No segment operating-profit split is disclosed, because DexCom disaggregates revenue only by geography and channel; no segment profit figure is stated here.

KEY RISKS

  • Reimbursement and coverage — G7 coverage depends on Medicare, Medicaid and commercial-payer eligibility rules; a coverage narrowing would hit volumes directly.
  • Competitive pricing — Libre and other CGM/biosensor rivals can force price or rebate pressure, and DexCom rebates to some entities are excluded from the customer-concentration table, so the combined disclosed share can exceed 100% (per the 10-K note).
  • Manufacturing concentration — sensors are made in a small number of plants (Mesa, Batu Kawan, Athenry); disruption at one site constrains supply.
  • Transition risk — moving G6 customers to G7/G7 15 Day by end-2026 must hold retention; slippage would show up in distributor orders first.
  • Regulatory change — as a Class II device maker, DexCom faces 510(k) special controls; a control change can delay new wear-time or feature claims.

WHY IT MATTERS FOR THE S&P 500

DexCom is the S&P 500’s pure-play CGM name at a 0.05% weight and Health Care rank #42: it gives the index its cleanest exposure to diabetes-technology adoption, sensor volumes and the shift from fingerstick testing to continuous data.

Its results are also a read on consumer-health reimbursement: payer coverage decisions and distributor sell-through move DexCom revenue before they move broader medical-device demand.

SOURCES & METHODOLOGY

Market dataSlickcharts S&P 500 by weight (rank, weight, price — Nov 3, 2026 crawl) · StockAnalysis (market cap — Nov 3, 2026 crawl, single source)
FinancialsDexCom FY2025 Form 10-K (fiscal year ended Dec 31, 2025; filed Feb 12, 2026, SEC EDGAR)
Sector classificationGICS via the List of S&P 500 companies (Wikipedia)
Library dataSPXSet logo library, compiled from company official websites, filings, or Wikipedia; as company logos are dynamic corporate information, no 100% guarantee is made for the graphics. SPXSet chart library, monthly bars, compiled from Yahoo public information.

Price Chart — 10-Year Monthly Candles

Dexcom

Source: Yahoo Finance monthly bars, split-adjusted · Data as of Sep 30, 2026 (last closed month) · SPXSet.com

FINANCIALS

繁體中文版

公司快照

股票代號DXCM(Nasdaq)
公司DexCom, Inc.
GICS 板塊/行業醫療保健/Health Care Equipment
標普500排名(按權重)第314名 · 0.05%(2026 年 11 月 3 日)
板塊內排名(按標普500權重)醫療保健第42名(2026 年 11 月 3 日)
總部美國加州聖地牙哥
成立1999年
行政總裁Jacob S. Leach
員工約11,100人(2025年12月31日,FY2025 10-K)
市值$31.61B(2026 年 11 月 3 日)
SEC 文件EDGAR — CIK 0001093557

業務概覽

德康設計、製造及銷售連續血糖監測(CGM)系統,用於糖尿病及代謝健康管理。G7系統已在美國獲批供兩歲及以上糖尿病患者使用,G7 15 Day系統於2025年4月獲批供成人使用,可提供即時血糖讀數,無需常規指尖採血,並可連接手機、手錶及胰島素輸送合作夥伴產品。

FY2025收入為46.620億美元,較FY2024的40.330億美元增長16%;淨利潤為8.363億美元,較5.762億美元增長45%。毛利為28.019億美元,毛利率60.1%(計算值:毛利除以收入)。美國佔收入71.5%,國際市場佔28.5%。德康透過經銷商銷售(佔收入84.9%,計算值)及直接銷售(15.1%,計算值)。

除糖尿病外,德康於2024年8月推出Stelo,作為美國首款非處方血糖生物感測器,面向未使用胰島素的前期糖尿病及2型糖尿病成人。生產基地位於亞利桑那州梅薩、馬來西亞峇都加灣及愛爾蘭雅典萊,總部及研發中心位於聖地牙哥。

按地區劃分的收入 — FY2025

板塊收入佔比同比
美國$3,334.9M71.5%+15%
國際$1,327.1M28.5%+16%
收入總計$4,662.0M100%+16%
來源:DexCom FY2025 10-K收入分拆附註。德康只有一項業務活動(CGM系統),按地區及銷售渠道分拆;FY2025渠道分拆:經銷商39.590億美元,直接銷售7.030億美元(佔比為計算值)。佔比及同比均按10-K比較數字計算;各行合計等於總數(四捨五入)。

歷史沿革

年份里程碑
1999年於加州聖地牙哥成立,開發連續血糖監測技術
2006年獲FDA批准並商業化首款CGM產品
2018年G6獲FDA上市許可,成為首款可作為綜合系統一部分與兼容設備配合使用的CGM
2023年G7推出;2022年12月獲FDA許可,2022年3月獲CE標誌
2024年Stelo於8月推出,成為美國首款非處方血糖生物感測器
2025年G7 15 Day於4月獲FDA上市許可;德康表示將於2026年底前把G6客戶轉移至G7及G7 15 Day

競爭地位

  • CGM類別領導地位 — 德康、雅培及美敦力主導處方CGM市場;德康以準確度(10-K稱G7 15 Day的MARD為8.0%)、佩戴時間、連接性及保險覆蓋競爭,而非僅靠價格。
  • 平台廣度 — 同一感測器平台服務強化胰島素使用者(G7)、長佩戴期成人(G7 15 Day)及非胰島素使用者(Stelo),把可觸及市場擴展至1型糖尿病以外。
  • 分銷覆蓋 — 經銷商佔收入84.9%,因此藥房及經銷商關係,而非僅直接銷售,決定市場准入與增長。
  • 競爭 — 雅培Libre、美敦力Guardian及新興生物感測器業者在準確度、價格及胰島素泵整合上競爭;10-K集中度披露指出,失去主要經銷商或付款方合約將屬重大。

財務快照 — FY2025

收入$4,662.0M(同比+16%)
銷售成本$1,860.1M
毛利$2,801.9M(毛利率60.1%,計算值)
研發$599.1M
銷售、一般及行政$1,291.0M
營業利潤$911.8M(FY2024為$600.0M)
淨利潤$836.3M(同比+45%)
攤薄每股收益$2.09(FY2024為$1.42)
總資產$6,339.9M(2025年12月31日)
股東權益$2,746.0M(2025年12月31日)
來源:DexCom FY2025 10-K合併報表。毛利率按10-K數字計算。由於德康僅按地區及渠道分拆收入,未披露分部營業利潤,故此處不列分部利潤數字。

主要風險

  • 報銷與覆蓋 — G7覆蓋取決於聯邦醫療保險、醫療補助及商業保險的資格規則;覆蓋收窄會直接打擊銷量。
  • 競爭定價 — Libre及其他CGM/生物感測器對手可帶來價格或回扣壓力;10-K附註指出,付予部分實體的回扣不計入客戶集中度表,因此披露的合計佔比可超過100%。
  • 生產集中 — 感測器僅在少數工廠生產(梅薩、峇都加灣、雅典萊),任一廠房中斷都會限制供應。
  • 轉換風險 — 須於2026年底前把G6客戶轉移至G7/G7 15 Day,留存率下滑會首先反映在經銷商訂單上。
  • 監管變化 — 作為二類醫療器械製造商,德康受510(k)特別控制約束;控制要求變化可延遲新佩戴期或功能聲明。

對標普500的重要性

德康是標普500中純CGM公司,權重0.05%,醫療保健板塊第42名:它為指數提供最直接的糖尿病技術採用、感測器銷量及從指尖採血轉向連續數據的敞口。

其業績亦是消費健康報銷的晴雨表:付款方覆蓋決定及經銷商銷售會先於整體醫療器械需求反映在德康收入上。

來源與方法

市場數據Slickcharts 標普500權重榜(排名、權重、價格——2026 年 11 月 3 日抓取)· StockAnalysis(市值——2026 年 11 月 3 日抓取,單一來源)
財務DexCom FY2025 10-K(財政年度截至2025年12月31日;2026年2月12日提交,SEC EDGAR)
板塊分類GICS,據 S&P 500 公司清單(Wikipedia)
圖庫數據SPXSet logo 庫,整理自企業官方網站、文件或維基百科;由於是企業自身動態資訊,不對圖形做百分百保證。SPXSet 圖表庫月線,整理自 Yahoo 公開資訊。

10年股價K線圖(月K)

Dexcom

來源:Yahoo Finance 月 K(經拆股調整)· 數據截至 2026 年 9 月 30 日(最後已收月份)· SPXSet.com

財報

SPXSet Studio

SPXSet in-house research — market structure, options and volatility. Not investment advice.
SPXSet 站內獨立研究,聚焦 SPX 市場結構、期權與波動率;內容不構成投資建議。

SPXSet · Company Library · DXCM
Data as of Nov 3, 2026 · Financials FY2025 (10-K) · Market data Nov 2026
Previous · Raymond James Financial, Inc. (RJF) — XLF Financials · S&P 500 Profile |雷蒙德詹姆斯公司介紹Next · Ingersoll Rand Inc. (IR) — XLI Industrials · S&P 500 Profile |英格索蘭公司介紹

Entered 2026-11-03 08:26 · updated 2026-11-14 23:21 · rev 6